Welcome to LifePulse
A Quantum Advance for PEF – The Intellipulse TM System
For the first time in a generation the science of PEF (pulsed electrical fields) has changed. Built with the veterinarian and the patient in mind, the VetPulse 2000 is the first of its kind in the world. With hundreds of successful treatments since March 2022, the VetPulse 2000 is now the standard for electrochemotherapy. Patented and trademarked, the Intellipulse™ system incorporates moderate heat, real time impedance feedback and addressable electrodes, making it the only device ever built that assures delivery and makes either over or under treatment impossible.
™
™
™
US Engineered and Manufactured
LifePulse VetPulse 2000 is the product of more than 15 patents and $35M of R&D over two decades
The VetPulse 2000 provides effective treatment of tumors as a part of adjuvant, neoadjuvant, or palliative care in horses, dogs, cats, exotics and marine life. Dr Richard Heller and Dr Mark Jaroszeski, the leading scientists in the field, have spent the last three decades perfecting PEF technology. The result is a medical device like nothing that has ever been produced. Able to detect tissue impedance feedback in real time and using less than half the energy of any other device, the VetPulse 2000 is the only US engineered and manufactured device of its kind. We created our device with the end user in mind, making it simple to use and giving the practitioner assurance of delivery, reduced risk of healthy tissue damage and the peace of mind knowing you are using the most advanced, safe and effective method for treatment available.
Reproducable Results
. Numerous studies have proven both the efficacy and safety of this modality in the treatment of cancerous tumors in equine, feline, and canine subjects in the US and abroad. Dr Richard Heller, and Dr Mark Jaroszeski, the leading scientists for this technology worldwide, have produced more than 100 patents and nearly 100 publications in their quest for the quantum leap forward we have achieved. For years, many vets have been reluctant to incorporate the technology in their practice because of the high voltage, inability to monitor delivery and potential damage to the animal. Now for the first time, practitioners know in real time that delivery of their chosen therapeutic was successful. Veterinarians familiar with the technology are both relieved and excited about the important changes in the VetPulse 2000
Indications
Companion Animals
- Soft tissue sarcoma
- Squamous cell carcinoma
- Epulis
- Mast Cell Tumors
- Melanoma
- Osteo Sarcoma
- Feline Injection Site Sarcoma
- Localized cutaneous lymphoma
- Perianal and rectal tumors
- Vaginal tumors
- Mammary tumors
- Some internal tumors
- Adenocarcinoma
- Delivery of immunotherapy and vaccines
Equine
- Squamous cell carcinoma
- Dermal Melanomatosis
- Perianal and Rectal Tumors
- Vaginal tumors
- Mammary tumors
- Hoof Canker
- Nasal tumors
- Penile shaft tumors
- Periorbital tumors
- Fibroid Sarcoma
- Adenocarcinoma
- Lipoma
- Lyposarcoma
Portable, Affordable, and Effective
VetPulse 2000
- Simple to use device designed with the veterinarian in mind
- Treats many types of tumors in horses, dogs, and cats
- Allows for the enhanced delivery of any therapeutic and increased drug absorption
- Proven efficacy with high success rates and low reoccurrence rates
- No or minimal systemic side effects
- New technology virtually eliminates necrosis and risk of healthy tissue damage
- Can be repeated with equal or improved efficacy
- Can be used with cytotoxic, non-cytotoxic or no therapeutic
VetPulse 2000 is the first US engineered and manufactured therapeutic delivery device and the first quantum leap forward in the technology in a generation. Proven efficacy, the safest and most predictable device ever made, the VetPulse 2000 was designed with advice of Chelsea Tripp, DVM, DACVIM, (O), the leading user of the technology for many years. From ergonomics to functionality, the device was engineered with clinical use in mind.